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RESULTS: In all, 28,142 people were included in the co-
hort (12,945 olanzapine users and 15,197 risperidone us-
ers). The risk of developing diabetes was higher for those
exposed to olanzapine than for those exposed to risperi-
done, but this increase in risk was marginally statistically
significant (IRR: 1.209, 95 % CI: 1.001–1.460).
CONCLUSION: Compared to risperidone users, olanza-
pine users have a slightly higher risk of developing diabe-
tes. There is a need to extend this study over a longer ob-
servation period, as the risk of developing diabetes after
exposure to antipsychotic drugs is likely to increase with
time.
PDG3
AN ECONOMIC EVALUATION OF 
COMBINATION THERAPY WITH 
PIOGLITAZONE (ACTOS, TAKEDA) IN TYPE 2 
DIABETES MELLITUS FROM A SPANISH 
HEALTH-CARE PERSPECTIVE
Maniadakis N1, Sacristan J2, Reviriego J2, Hart W3, Jansen R4, 
Kielhorn A4, Brandt A5
1Eli Lilly, Windlesham Surrey, United Kingdom; 2Eli Lilly, Madrid, 
Spain; 3Health Outcomes, Madrid, Spain; 4Eli Lilly, Windlesham, 
Surrey, United Kingdom; 5Institute for Medical Informatics and 
Biostatistics (IMIB), Riehen, Switzerland
OBJECTIVE: To assess the cost-effectiveness of pioglita-
zone (PIO) in combination therapy versus usual care for
patients with type2 diabetes.
METHODS: A published, validated model for type1 dia-
betes mellitus developed by IMIB was adapted to simu-
late long-term management, health outcomes, resource
utilisation and treatment costs of patients with type2 dia-
betes. The model accounts for most complications in dia-
betes patients: nephropathy, retinopathy, acute myocar-
dial infarction, angina pectoris, stroke and amputation.
The analysis was done from a third-party-payer perspec-
tive and costs figured relative to the year 2000. A 6% dis-
count rate was applied and sensitivity analysis was per-
formed to test the results.
RESULTS: PIO 30 mg in combination with metformin
(MF) was associated with a higher life expectancy (14.82
years) than sulphonylureas (SU)/MF (14.03 years) or
rosiglitazone (RSG 8 mg/MF (14.67 years). Also, PIO-
based combinations were associated with the lowest
number of complications and deaths. For every 31 pa-
tients treated with PIO 30 mg /MF rather than SU/MF or
17 patients, respectively, for PIO 30 mg/SU rather than
MF/SU one complication was avoided. For every 27 pa-
tients treated with PIO 30 mg/SU instead of MF/SU, one
death was avoided. PIO was more expensive, but this was
offset by reductions in complications. The average pa-
tient-lifetime incremental total treatment cost with PIO
over alternatives ranged from 220,983 Spain Pesetas
(ESP) to 2,952,973 ESP. The undiscounted incremental
cost per life year gained (ICPLYG) of PIO 30 mg/MF rel-
ative to SU/MF was 3,660,692 ESP and relative to RSG
8 mg/MF 1,494,369 ESP. The discounted figures were
6,578,162 ESP and 1,913,919 ESP, respectively. The
ICPLYG of PIO 30 mg/SU relative to MF/SU was 3,344,145
ESP and 6,013,419 ESP after discounting. Finally, after
discounting, PIO 15mg/SU versus MF/SU and RSG 4 mg/SU
was associated with an ICPLYG of 7,556,100 ESP and
578,172 ESP, respectively.
CONCLUSION: Combined treatments with pioglitazone
improve survival and reduce complications in patients
with type 2 diabetes and represent cost-effective use of
scarce resources when judged against other therapeutic
interventions. It is necessary to confirm the results of this
model once long-term effectiveness data with the com-
pared alternatives are available.
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OBJECTIVE: Ischemic heart disease is the commonest
cause for morbidity and mortality in patients with diabe-
tes mellitus Type II (DMII). Treatment with biguanide
drugs has a beneficial effect on lipid profile, decreases in-
sulin resistance, procoagulant activity and body weight.
Drugs from the sulphonylurea group cause an increase in
insulin secretion, insulin resistance and weight gain. The-
oretically, lower rates of cardiovascular events would be
expected in patients treated with biguanides. The UKPDS
study showed decreased cardiovascular mortality in
obese diabetics, but several recent studies reported in-
creased mortality with metformin use. The objective of
our study was to compare cardiovascular disease in pa-
tients receiving either metformin or sulphonylurea.
METHODS: We compared the rates of revascularization
procedure in the year 2000 between patients with DMII
that were treated either with metformin or glibenclamide.
All received the drugs for at least five years. Demographic
parameters were similar between the groups. Data were
obtained from the computerized database of the largest
HMO in the country.
RESULTS: 140,757 patients were included in the study.
50.3% were on metformin and 49.7% on glibenclamide.
7601 underwent cardiac revascularization procedures. Of
these, 53 % were on glibenclamide and 47% on met-
formin. The risk of undergoing a revascularization proce-
dure was 1.13 times higher in patients treated with glib-
enclamide (P  .01).
CONCLUSION: The results of our study indicate that
patients with DMII treated with metformin have a lower
rate of cardiovascular procedures than patients treated
with glibenclamide. The use of this group of drugs may
decrease the morbidity, mortality and costs in diabetic
patients. More studies that include additional end points
are needed.
